Want to see TLSI full AI Analyst Report?
TLSI Stock Chart & Stats
$4.65
-$0.05(-0.97%)
At close: 4:00 PM EST
$4.65
-$0.05(-0.97%)
Day’s Range― - ―
52-Week Range$2.20 - $7.95
Previous CloseN/A
Volume4.84K
Average Volume (3M)672.78K
Market Cap
$279.45M
Enterprise Value$125.40M
Total Cash (Recent Filing)$56.55M
Total Debt (Recent Filing)$34.49M
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Aug 19, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.41
Shares Outstanding61,416,534
10 Day Avg. Volume434,043
30 Day Avg. Volume672,784
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)-10.14
Price to Sales (P/S)7.60
P/FCF Ratio-18.14
Enterprise Value/Market Cap0.45
Enterprise Value/Revenue2.79
Enterprise Value/Gross Profit3.28
Enterprise Value/Ebitda-5.99
Forecast
1Y Price Target
$9.00Price Target Upside93.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.32
Revenue Forecast (FY)$53.67M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained mid-80s gross margins reflect low unit COGS and manufacturing improvements, giving durable unit economics. This margin profile supports future operating leverage as volumes scale, improving the path to profitability once commercial traction and device adoption increase.
Strong Clinical Evidence For PEDDRobust real-world evidence and multiple active trials provide durable clinical validation for PEDD, strengthening physician adoption, payer engagement, and partner interest. Evidence of meaningful downstream cost avoidance supports reimbursement discussions and competitive differentiation long term.
Commercial Build And Leadership HiresA materially expanded commercial footprint and senior sales leadership create sustained go-to-market capacity. While reps need 6–9 months to ramp, this investment establishes durable distribution capability and market coverage needed to capture multi‑year addressable markets.
Bears Say
Sharp Revenue ContractionA severe TTM revenue decline undermines operating leverage and raises questions on demand stability and commercial execution. Persistent top-line weakness prolongs the path to profitability and limits the company’s ability to scale fixed costs or invest without external funding.
Ongoing Cash BurnConsistent negative operating and free cash flow means the business is not self-funding and will rely on financing to execute growth. That dependence can dilute shareholders, restrict strategic optionality, and compress runway if commercial or regulatory timelines slip versus plan.
Regulatory Timing Risk For TriNav AdvanceA prolonged FDA review delays product launch and associated revenue, creating uncertainty in the commercialization cadence. Timing risk affects reimbursement discussions, rep incentive payoff, and cash planning, potentially forcing slower rollouts or additional capital needs.
TriSalus Life Sciences News
TLSI FAQ
What was Trisalus Life Sciences, Inc.’s price range in the past 12 months?
Trisalus Life Sciences, Inc. lowest stock price was $2.20 and its highest was $7.95 in the past 12 months.
What is Trisalus Life Sciences, Inc.’s market cap?
Trisalus Life Sciences, Inc.’s market cap is $279.45M.
When is Trisalus Life Sciences, Inc.’s upcoming earnings report date?
Trisalus Life Sciences, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 48 days.
How were Trisalus Life Sciences, Inc.’s earnings last quarter?
Trisalus Life Sciences, Inc. released its earnings results on May 12, 2026. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of -$0.158 by $0.188.
Is Trisalus Life Sciences, Inc. overvalued?
According to Wall Street analysts Trisalus Life Sciences, Inc.’s price is currently Undervalued.
Does Trisalus Life Sciences, Inc. pay dividends?
Trisalus Life Sciences, Inc. does not currently pay dividends.
What is Trisalus Life Sciences, Inc.’s EPS estimate?
Trisalus Life Sciences, Inc.’s EPS estimate is -0.15.
How many shares outstanding does Trisalus Life Sciences, Inc. have?
Trisalus Life Sciences, Inc. has 61,416,534 shares outstanding.
What happened to Trisalus Life Sciences, Inc.’s price movement after its last earnings report?
Trisalus Life Sciences, Inc. reported an EPS of $0.03 in its last earnings report, beating expectations of -$0.158. Following the earnings report the stock price went down -41.447%.
Which hedge fund is a major shareholder of Trisalus Life Sciences, Inc.?
Currently, no hedge funds are holding shares in TLSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TriSalus Life Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.00 (93.55% Upside)
$9.00 (93.55% Upside)
Blogger Sentiment
Bullish
TLSI Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 109.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 14.4%
Last 30 Days ▼ 14.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.90%
12-Months-Change
Fundamentals
Return on Equity
162.57%
Trailing 12-Months
Asset Growth
147.96%
Trailing 12-Months
Company Description
Trisalus Life Sciences, Inc.
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.
TLSI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized a major clinical and economic validation of PEDD (landmark real-world study, strong pipeline, meaningful early results in multiple new indications) and a deliberate commercial build intended to capture a large addressable market. Near-term financials were impacted by the deliberate salesforce expansion (temporary revenue disruption, higher operating losses) and a regulatory delay for TriNav Advance that defers some expected second-half revenue. Management positions the investments as strategic and funded by a solid cash balance, with expectations of sustained ramp and commercial momentum through the remainder of 2026 and beyond.View all TLSI earnings summariesTLSI Stock 12 Month Forecast
Average Price Target
$9.00
▲(93.55% Upside)
Technical Analysis
Ownership Overview
28.22% Insiders
6.64% Mutual Funds
22.90% Other Institutional Investors
36.45% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---